The neurological sequelae of pandemics and epidemics

Fernanda Valerio\textsuperscript{1} · Daniel P. Whitehouse\textsuperscript{1} · David K. Menon\textsuperscript{1,2} · Virginia F. J. Newcombe\textsuperscript{1,2}

Received: 30 June 2020 / Revised: 3 October 2020 / Accepted: 7 October 2020 / Published online: 26 October 2020
© The Author(s) 2020

Abstract

Neurological manifestations in pandemics frequently cause short and long-term consequences which are frequently overlooked. Despite advances in the treatment of infectious diseases, nervous system involvement remains a challenge, with limited treatments often available. The under-recognition of neurological manifestations may lead to an increase in the burden of acute disease as well as secondary complications with long-term consequences. Nervous system infection or dysfunction during pandemics is common and its enduring consequences, especially among vulnerable populations, are frequently forgotten. An improved understanding the possible mechanisms of neurological damage during epidemics, and increased recognition of the possible manifestations is fundamental to bring insights when dealing with future outbreaks. To reverse this gap in knowledge, we reviewed all the pandemics, large and important epidemics of human history in which neurological manifestations are evident, and described the possible physiological processes that leads to the adverse sequelae caused or triggered by those pathogens.

Keywords  CNS infections · Peripheral neuropathies · Pandemics/history · Meningitis · Encephalitis

Introduction

Pandemics are large-scale outbreaks of infectious disease that can cause an excess in morbidity and mortality globally, or at least over a wide geographic area, and lead to socioeconomic disruption. Increase in global travel, urbanisation, climate change, environmental degradation, displacement and consumption of wild animals are factors thought to have increased the likelihood of pandemics during the past century [79]. The majority of pathogens responsible for outbreaks can cause neurologic illness, which are frequently overlooked, under-reported and under-diagnosed. Even in tertiary centres of developed countries, up to 30\% of patients with a CNS infection never receive an etiological diagnosis [135], and in low resource settings lacking diagnostic tools, neurological manifestations are often poorly characterised. Aside from the associated mortality, neurological involvement of infectious disease can lead to prolonged hospital stay and significantly increase rehabilitation time and long-term care needs after discharge [135], posing a far-reaching socioeconomic burden.

As the world deals with the Sars-CoV2 pandemic, reports of neurologic manifestations have increased. Understanding neurological complications of previous pandemics, and the pathophysiological mechanisms that underlie them, are fundamental to place the current situation in perspective, and help address the enduring consequences once current waves of acute infection subside. This narrative review assesses the neurological manifestations of past and current pandemics, to aid our understanding of the current pandemic and prepare for future outbreaks.

Mechanisms of pathogen-mediated neurological disease

Pathogens can lead to nervous system impairment through multiple mechanisms. There may be direct infection and replication leading to the clinical syndromes of encephalitis, myelitis and meningitis [65]. Para-infectious complications such as sepsis and metabolic dysfunction related and coagulopathy can lead to encephalopathy and vascular events.
The infection can also trigger an indirect immune-mediated attack both in the central and peripheral nervous system [32], as seen in Guillain–Barré syndromes (GBS) or acute disseminated encephalomyelitis (ADEM). Finally, some viruses can persist mutated or latent in the central nervous system (CNS) or peripheral ganglia, leading to potential late reactivation and clinical disease. Further details are provided in Table 1; Fig. 1.

Pathogens responsible for pandemics and important epidemics throughout history

Pathogens are divided according to the main mode of transmission (vector-borne, water/food-borne and direct or indirect with infected individuals). Its features, including notable pandemics, non-neurological and neurological manifestations may be found in Fig. 2 and Table 2. We have summarised imaging and laboratory findings in Table 3. A more complete description of the neurological manifestations follows.

Vector-borne

Bubonic plague

The first Plague pandemic, known as the Plague of Justinian, occurred during the sixth century and is believed to have hastened the end of the Roman Empire. The second commenced with a wave known as the “Black Death” and is estimated to have resulted in the deaths of over 100 million people; the highest of any pandemic in history. Currently, most human cases are located in Africa, and annual epidemics are reported in Madagascar [156]. Meningitis is reported in up to 7% of all patients, typically after the 1st week in those who received incomplete or delayed treatment for the bubonic form. Younger patients have higher incidence of Yersinia meningitis (around 11% of children) [8, 14, 82]. It presents as a bacterial meningitis, with neutrophilic pleocytosis in the CSF. The gold standard for diagnosis is the culture of Y. pestis in blood, sputum, bubo aspirate or CSF, but the bacteria can also be detected using point of care testing with immunochromatographic assays or quantitative PCR in portable thermocyclers [35, 158].

West Nile virus (WNV)

This virus was first identified in the West Nile province of Uganda in 1937 [122]. In 1999 an outbreak occurred in New York which spread to the rest of the Americas, leading to the largest epidemics of meningitis or encephalitis ever reported in the western hemisphere [69]. Under 1% of infected individuals developed the neuroinvasive disease, but the incidence is higher among those >65 years, which also have higher mortality. The neurologic syndromes can overlap and be divided in meningitis, meningoencephalitis, and acute flaccid paralysis secondary to anterior myelitis and typically occurs in the acute phase of the disease. Extrapyramidal signs are seen in some encephalitic cases during the acute illness, and may be transient or last months after the resolution of the disease. Seizures and encephalopathy have also been reported [123].

Japanese encephalitis

Large epidemics of Japanese encephalitis Virus (JEV) occur every 2–15 years in South-East Asia and Western Pacific, making it the world’s most commonly diagnosed epidemic encephalitis (~70,000 cases/year). Among the arthropod-borne viruses, JEV leads to the greatest loss of disability-adjusted life years, due to the frequent neurological sequelae of the condition. While the majority of infections are asymptomatic or mild, 0.1–1% cause encephalitis, mainly in children. It manifests in the acute phase of the disease. Symptoms include impaired consciousness, headache, vomiting, and seizures. Pyramidal and extrapyramidal signs, involvement of cranial nerves, eye movement abnormalities and anterior myelitis are described. Similar neurological features are seen in adults. Other immunological manifestations include GBS, ADEM, transverse myelitis and N-methyl-D-aspartate (NMDA) receptor encephalitis, weeks after the onset of the viral illness. Approximately one-fifth of patients with JEV-encephalitis die and 44% of those with neurological involvement have incomplete recovery [140].

Zika

The Zika virus was described in Uganda in 1947 and has caused outbreaks in Asia and the Pacific. In 2014–2016 it caused an epidemic of microcephaly among newborns in the northeast of Brazil [31]. The congenital Zika syndrome occurs in 5–14% of pregnancies of infected mothers, and includes severe microcephaly, skull collapse, subcortical calcifications, corpus callosum anomalies, decreased white matter, ventriculomegaly, cerebral cortex thinning, abnormal gyral patterns, vermis hypoplasia, chorioretinal atrophy, focal pigmented mottling of the retina, optic nerve atrophy and congenital contractures [90, 94]. Zika virus-associated GBS (both axonal and demyelinating) has been described 5–15 days after the acute disease [94].

Chikungunya fever

Chikungunya virus was isolated during an outbreak in 1952 in Tanzania, and significant epidemics have been described
Table 1  Mechanisms of pathogen-induced neurological injury

| Mechanisms | Description | Neurologic manifestations |
|------------|-------------|------------------------|
| **Direct invasion** | | |
| Blood brain barrier (BBB) (haematological entry) | Penetration of endothelial barriers via (BBB disruption associated with acute host inflammatory responses may facilitate invasion): Transcellular penetration (using pinocytosis or receptor-mediated entry) Paracellular entry (by disrupting tight junctions) Via entry of infected leukocytes from the peripheral circulation into the CNS (Trojan horse mechanism) [28, 65] | Encephalitis Meningoencephalitis Meningitis Anterior myelitis Encephalopathy |
| **Peripheral nerves (trans-synaptic spread)** | Pathogens: Move along peripheral nerves via retrograde (from axon terminal to cell body) or anterograde (from cell body to axon terminal) transport | |
| | Invade the PNS by binding to receptors on axons of sensory, autonomic and motor neurons, including the olfactory and vagal nerves [68, 77, 84, 116, 142] | |
| **Para-infectious** | Sepsis-associated | Diffuse disturbance of brain function as a consequence of the systemic inflammatory response of sepsis [45, 148] Presents as impaired attention and arousal [165] Release of inflammatory mediators affecting both the BBB and the cerebral microcirculation [120] (“cytokine storm”) | Encephalopathy Acute haemorrhagic leukoencephalitis (AHL) |
| | Secondary to metabolic dysfunction | Can be isolated or in the context of sepsis and organ failure: Severe hypoxia Shock-induced hypoperfusion Metabolic disturbances Electrolyte imbalances (hyponatremia or hypernatremia, hypocalcaemia or hypercalcaemia) | Seizures Encephalopathy Diffuse ischaemia |
| | Secondary to coagulopathy and vasculitis | Hyperinflammation in SIRS and sepsis leads to coagulopathy and a prothrombotic state Both direct pathogen invasion and the proinflammatory state of sepsis lead to endothelial damage [144], which then shifts to a procoagulant state and has increased vascular permeability [57, 126] Infections may cause vasculitis, either due to pathogen invasion, exaggerated immune response, or immune dysregulation triggered by bacterial toxins or antigens [136] | Stroke Cerebral venous thrombosis Intracranial haemorrhage Peripheral neuropathy |
| **Post-infectious** | Autoimmune | Triggered especially by viruses, which serve as antigens and lead to lesions of the PNS and CNS Associated with molecular mimicry between the pathogen and molecules on the axolemmal surface, glial membranes at the node of Ranvier [150] or myelin proteins of the host, which leads to T-cell activation and an autoimmune response [106] | Guillain-Barré syndromes Acute disseminated encephalomyelitis (ADEM) Transverse myelitis Acute motor axonal neuropathy (AMAN) Acute inflammatory demyelinating polyneuropathy (AIDP) |
worldwide. The most recent started in 2013, affecting the Southern USA, Mexico, Central and South America, with over 2 million infections reported [146]. Young children and older adults are at a higher risk of complications, which may affect approximately one percent of infected individuals. Encephalopathy and encephalitis are caused by direct viral invasion and manifest early during the infection [19]. Myelitis can occur either in the acute phase or later in the course of the disease. Tardive post-infectious complications, thought to be autoimmune in nature, include ADEM, optic neuropathy, GBS, brainstem encephalitis and Bickerstaff’s encephalitis-Miller-Fisher overlap [19].
Water or food-borne

Enteroviruses

Enteroviruses cause over 90% of viral meningitis in children under 10 years and is most frequently by echoviruses and Coxsackie-B [77]. Two enteroviruses that caused epidemics and remarkable neurological manifestations are detailed below.

Polio virus

Poliomyelitis was sporadically reported until the end of the nineteenth century, when large summer epidemics in North America and Europe began occurring annually [96]. The development and implementation of vaccination programmes since 1955 decreased its incidence dramatically, though outbreaks still occur in Africa and Asia, and it is endemic in Nigeria, Afghanistan and Pakistan. Around 1 in 150 infections will lead to paralytic poliomyelitis [96]. When the virus reaches the CNS, there is a meningitic phase followed by spinal poliomyelitis and onset of an acute flaccid paralysis secondary to anterior myelitis, early in the course of the infection. After a period of stable neurological function (≥15 years), 30–40% of polio survivors develop progressive and persistent new muscle weakness and increased fatigue, characterising the post-polio syndrome. The pathogenesis is not completely understood but thought to be related to a disturbance of the denervation/re-innervation equilibrium with further denervation. In 2016, it was estimated that there are 15–20 million polio survivors worldwide [76].

Enterovirus-71 (EV71)

This virus was isolated in 1969 and is a common cause of hand, foot, and mouth disease in children. Cyclical large epidemics occur in the Asian-Pacific region every 2–3 years and it circulates at a low level in the rest of the world, with small outbreaks in Europe, North America and Africa [130]. Children may develop CNS manifestations after 3–5 days of prodrome [100]. During an outbreak in Malaysia, 10–30% of hospitalised children had neurological manifestations, which included aseptic meningitis, encephalitis and acute flaccid paralysis.
### Table 2 Pandemics and selected epidemics in which neurological manifestations were reported

| Disease (pathogen)                          | Event/distribution            | Mode of transmission                                                                 | Incubation period | Non-neurological features                                      | Neurologic manifestations                                      | Mechanism of neurological injury | Treatment                                                                 |
|--------------------------------------------|-------------------------------|--------------------------------------------------------------------------------------|------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------|
| Bubonic plague (Yersinia pestis)           | 541: Justinian plague—Eurasia| Bite of infected rodents’ fleas Direct contact with infected bodily fluids, fomites, and inhalation of infected respiratory droplets | 1–7 days         | Initial symptoms are fever, malaise, myalgia. Lymphadenitis develops near the location of flea bite (bubo), characterizing the bubonic form. Other forms are the septicemic and pulmonary plague | Meningitis (may present late in the course of disease even in patients under antibiotics) | Direct invasion | Antibiotic therapy with chloramphenicol if plague meningitis. For other forms, gentamicin OR doxycycline OR ciprofloxacin can be used |
| West Nile (West Nile virus)                | Late 1990s: Romania, Russia, Israel 1999–2003: Americas | Bite by virus-carrying Culex mosquitoes. Birds are reservoirs in nature | 3–14 days        | Most infected are asymptomatic. Between 20 and 40% will develop a flu-like illness with fever, headache, malaise, myalgia, skin rash and gastrointestinal symptoms | Meningitis Encephalitis Anterior myelitis | Direct invasion | Supportive care. No controlled trial has successfully tested the efficacy of specific drugs |
| Japanese Encephalitis (Japanese encephalitis virus)* | Endemic in 24 countries of tropical South East Asia and West Pacific Large epidemics every 2–15 years in temperate areas of Asia | Bite by virus-carrying Culex mosquitoes. The virus exists in an enzootic cycle between birds and mosquitoes with pigs as amplifying hosts and humans as dead-end hosts | 5–15 days        | Vast majority of infections are either asymptomatic or very mild. If present, symptoms include self-limiting fever and eventual coryza and/or diarrhoea | Encephalitis Anterior myelitis GBS Transverse myelitis ADEM Associated with NMDA encephalitis | Direct invasion | Supportive care during the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Zika (Zika virus)                          | 2007: Yap island (western Pacific Ocean) 2013: French Polynesia 2014–2016: Americas 2016: Singapore, Vietnam, Thailand, Guinea-Bissau, Angola 2018: India | Bite of virus-carrying Aedes mosquitoes, sexual relations and blood transfusion. Vertically transmitted during pregnancy | 3–14 days        | Infected adults are either asymptomatic (50–80%) or have mild flu-like symptoms: fever, rash, arthralgia, conjunctivitis and myalgia. Maternal–foetal transmission occurs in 20–30% of cases, among which 4–7% will lead to foetal loss | Congenital Zika syndrome: microcephaly, subcortical calcifications, corpus callosum, cortex malformations, retinal alterations Meningoencephalitis Transverse myelitis GBS | Direct invasion | Supportive care during the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|-------------------|--------------------|----------------------|------------------|---------------------------|--------------------------|---------------------------------|-----------|
| Chikungunya fever (Chikungunya virus) | 1960s: Asia 2005–2007: Kenya, Indian Ocean islands, India, South East Asia 2007: Italy 2014: France 2014–current: Americas 2017–current: Pakistan | Bites of virus-carrying mosquitoes, predominantly *Aedes aegypti* and colder-climate tolerant *Aedes albopictus*. Other forms include: blood borne transmission, vertical transmission during 2nd trimester, intrapartum transmission when mother is viraemic during delivery | 3–7 days | Fever, polyarthralgia (usually bilateral and symmetric), headache, myalgia, conjunctivitis, arthritis, nausea, vomiting and maculopapular rash, for 7–10 days. Some patients persist with arthralgia for months to years after the acute disease | Acute encephalitis Meningoencephalitis GBS (including Miller Fisher and Bickerstaff’s syndromes) Transverse myelitis Myeloradiculitis ADEM Optic neuropathy | Direct invasion Post-infectious—autoimmune | Supportive care during the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Malaria (*Plasmodium falciparum*)** | Endemic with local outbreaks in 91 tropical and subtropical countries of Africa, Central and South America and Asia (nearly half of the world population). Eliminated from Europe in 1975 Epidemic potential expected to increase with increasing temperatures associated with climate changes | Mosquito bite of infective female *Anopheles*. Also, though blood transfusion, organ transplant, shared use of needles, and vertically during pregnancy | 9–14 days | Fever, headache, sweats, chills, malaise, myalgia, gastrointestinal symptoms The classical (but seldom observed) malaria attack lasts 6–10 h, consisting of a cold stage (shivering), a hot stage (fever, headaches, vomiting) and a sweating stage (sweats and fatigue) | Encephalopathy Seizures | Para-infectious—secondary to sequestration of erythrocytes into cerebral blood vessels, release of cytokines, BBB permeability and metabolic dysfunction | Supportive care during the acute phase including correction of metabolic dysfunction |
| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|-------------------|--------------------|----------------------|------------------|---------------------------|--------------------------|-------------------------------|------------|
| Yellow fever (yellow fever virus)* | Endemic in 47 countries of Africa, South and Central Americas; nineteenth century: USA, Europe (Atlantic ports), the Caribbean, Central America; 2016–current: expansion to non-endemic areas in Africa and South America | Mosquito bites from *Aedes* and *Haemagogus* species. Monkeys are also infected and are reservoirs in jungle areas | 3–6 days | Fever, myalgia, chills, backache, headache, lack of appetite, nausea and vomiting for 3–4 days. Some are asymptomatic. Between 15 and 25% of infected enter a second toxic phase with fever, vomiting, epigastric pain, renal failure, haemorrhagic diathesis, transaminase and direct bilirubin rise with deep jaundice | Febrile seizures in the acute phase (young children) | Direct invasion | Supportive care during the acute phase, including correction of metabolic dysfunction |
| Dengue (dengue virus)* | Evolved from sporadic cases in 1970s to endemic in over 100 countries worldwide with explosive outbreaks in new areas | Bite of virus-carrying mosquitoes, predominantly *Aedes aegypti* and colder-climate tolerant *Aedes albopictus*. Perinatal transmission occurs when the mother is infected near delivery. Breast milk and bloodborne transmission are also possible | 4–10 days | 40–80% are asymptomatic. Self-limiting symptoms last 5–7 days and include high fever, headache (specially retroorbital), myalgia, arthralgia and, rash. Around 5% will have the severe form of disease, manifest during the defervescence period (after the 1st week) in which there is plasma leakage due to increased vascular permeability, with or without bleeding and can lead to shock and severe organ involvement | Encephalopathy Aseptic meningitis ADEM Transverse myelitis GBS Mononeuropathies of cranial nerves Optic neuropathy Muscle dysfunction Intracranial haemorrhages | Direct invasion | Supportive care during the acute phase and for para infectious manifestations. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Disease (pathogen)                  | Event/distribution                                                                 | Mode of transmission                                                                 | Incubation period | Non-neurological features                                                                 | Neurologic manifestations                  | Mechanism of neurological injury | Treatment                                                                 |
|-----------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------|----------------------------------------------------------------------------|
| Poliomyelitis (Poliovirus)        | End of nineteenth century—1955: Large cyclical outbreaks during summer on Northern Europe and United States 2008: Nigeria and West Africa | Oral-faecal route by ingestion of contaminated water or food. The virus multiplies in the oropharyngeal and intestinal mucosa from where it spreads for target organs, including the CNS | 7–10 days         | Most infections are either asymptomatic or accompanied by mild flu-like symptoms like fever, fatigue, headache and vomiting | Anterior myelitis Meningitis Encephalitis Post-polio syndrome | Direct invasion | Supportive care. Rehabilitation in the chronic phase |
| Enterovirus-71 (Enterovirus-71)*  | Cyclical epidemics in the Asia-Pacific region every 2–3 years 1970s: Japan, Bulgaria and Hungary 1980s: Hong Kong, Australia 1997–1998: Malaysia, Japan, Taiwan 2008—China | Oral-faecal route by ingestion of contaminated water or food. The virus multiplies in the oropharyngeal and intestinal mucosa from where it spreads for target organs, including the CNS | 3–10 days         | In children, it can cause hand-feet-mouth disease: childhood exanthema with fever, papulovesicular rash on the palms and soles and oral ulcers, manifesting also as upper respiratory tract infection and gastroenteritis. Adults are frequently asymptomatic | Encephalitis, mainly brainstem Aseptic meningitis Encephalomyelitis Cerebellar ataxia Anterior myelitis Transverse myelitis GBS Myoclonus-opso- clonus | Direct invasion | Supportive care during the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Variant Creutzfeldt-Jakob disease (bovine spongiform encephalopathy [BSE] prion) | 1985: Bovine spongiform encephalopathy (BSE) described 1995: Beginning in the UK and spread to 13 countries | Ingestion of contaminated food (especially bovine meat), and rarely via blood transfusion or organ transplantation | 15–20 years       | Symptoms are eminently associated with the CNS infection | Psychiatric manifestations: depression, delusions, hallucinations Sensory disturbances, especially pain Dementia Ataxia Movement disorders: myoclonus, chorea, tremor | Direct invasion | Symptomatic management of neuropsychiatric disturbances. Palliative care during the inexorable last stages of the disease |
Table 2 (continued)

| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|--------------------|---------------------|----------------------|-------------------|---------------------------|--------------------------|---------------------------------|-----------|
| Cholera (Vibrio cholerae) | 1817–1824: 1st Cholera pandemic—Asia, Middle East, Caspian Sea basin | Oral-faecal route by ingestion of contaminated food or water | 12 h–5 days | Most infected are asymptomatic but still display faecal shedding of the bacteria. Symptoms can range from mild to severe and include watery diarrhoea and vomiting. Stools can resemble rice water, with flakes of mucus, with a fishy odour. There is no fever. Dehydration can rapidly ensue, potentially leading to hypovolemic shock | Seizures, secondary to electrolytic disturbances | Para-infectious—secondary to metabolic dysfunction | Aggressive rehydration and electrolyte disturbances correction (both oral and intravenous), antibiotic therapy with Doxycycline (1st line for adults) or azithromycin (1st line for children and pregnant women) for the moderately and severely ill patients, zinc supplementation (among children) |
| | 1829–1837: 2nd Cholera pandemic—Europe, Egypt, North America | | | | | | |
| | 1846–1860: 3rd Cholera pandemic—Europe, North America, Asia, Middle East | | | | | | |
| | 1863–1875: 4th Cholera pandemic—Asia, Europe, Africa, North America | | | | | | |
| | 1881–1896: 5th Cholera pandemic—Europe, Japan, Persia, Egypt | | | | | | |
| | 1899–1923: 6th Cholera pandemic—Russia, Ottoman Empire, Philippines, USA | | | | | | |
| | 1961–1975: 7th Cholera pandemic—Indonesia, Bangladesh, Soviet Union, North Africa, Italy | | | | | | |
| | 1991–94: South America, DRC (then Zaire) | | | | | | |
| | 2010—Haiti, Dominican Republic | | | | | | |
| | 2011–2018—Nigeria, DRC, Ghana, Sierra Leone, Ghana, Tanzania, Somalia, Algeria, Zimbabwe | | | | | | |
| | 2017–current: Yemen | | | | | | |
| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|--------------------|--------------------|----------------------|------------------|---------------------------|--------------------------|-------------------------------|-----------|
| Flu (influenza virus) | 1889: Russian Flu—started in Siberia and Kazakhstan (H3N8), spread to Europe and Asia 1918–1920: Spanish Flu (H1N1)—first observed in Europe and USA before going global 1957: Asian Flu (H2N2)—start in Hong Kong, spread to China, USA and Europe 1968: Hong Kong flu (H3N2)—global 2009: Swine flu (H1N1 pdm09)—global | Direct contact with respiratory droplets from infected people or fomites | 1–4 days | Common symptoms include fever, chills, cough, sore throat, runny nose, myalgia, headache, fatigue, gastrointestinal symptoms (more frequent in children). Complications include pneumonia, myocarditis and sepsis. Pregnant women, those aged < 5 or > 65 and who have underlying health conditions are at increased risk of complications | Aseptic meningitis Encephalitis Encephalopathy Stroke Acute necrotising encephalitis Kleine-Levin syndrome GBS Transverse myelitis Encephalopathic condition of Reye’s syndrome Encephalitis lethargica Post-encephalitic encephalopathy | ? Direct invasion Para-infectious—septic-related Para-infectious—secondary to metabolic dysfunction Para-infectious—secondary to coagulopathy Post-infectious—autoimmune | Supportive care. Both oseltamivir and high dose corticosteroids can be used in the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
| Coronaviruses (Sars-CoV, MERS-CoV, Sars-CoV2) | 2002–03: Sars-CoV—global (30 countries), start in China 2012: MERS-CoV 22 countries, start in the middle East 2019: Sars-CoV2—global | Direct contact with infected people’s respiratory droplets or fomites | 2–14 days | Some are asymptomatic. For these coronaviruses most will develop mild upper respiratory tract symptoms such as cough, sore throat, coryza, fever, chills, fatigue, myalgia, headache, nausea. A parcel will evolve with severe pneumonia and respiratory failure | Encephalopathy Meningoencephalitis Acute necrotising encephalitis Optic neuritis Stroke Myopathy GBS (including Miller Fisher and Bickerstaff’s syndromes) Mononeuropathies of cranial nerves ADEM | Direct invasion Para-infectious—septic-related Para-infectious—secondary to metabolic dysfunction Para-infectious—secondary to coagulopathy and vasculitis Post-infectious—autoimmune | Supportive care during the acute phase. Post infectious autoimmune conditions receive the standard immunomodulatory treatment for the condition |
### Table 2 (continued)

| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|--------------------|--------------------|----------------------|-------------------|---------------------------|--------------------------|---------------------------------|-----------|
| **Ebola (Ebola virus)** | 1976: Sudan, DRC (then Zaire) 1995–1997: Gabon, DRC (then Zaire) 2001–2003: Uganda, Gabon, Republic of Congo 2007–2009: DRC, Uganda 2013–2016: Guinea, Liberia, Sierra Leone, Nigeria, Mali, Senegal, Italy, USA, Spain, United Kingdom 2018–current: DRC, Uganda | Contact with virus-carrying bats (main reservoir) or with infected wild animals (intermediary hosts). It easily spreads via direct contact with bodily fluids or fomites (caring for the sick and handling deceased patients is particularly high risk). Also transmitted via sexual contact (up to 12 months after the acute infection) | 2–21 days | Early symptoms include high fever, malaise and body aches for 3 days, evolving to gastrointestinal symptoms which include nausea, large-volume diarrhoea and vomiting for 7–10 days. At this stage, some patients will go into shock and can present with haemorrhagic manifestations (conjunctival, gastrointestinal and mucosal bleeding) | Meningoencephalitis Encephalopathy Post Ebola syndrome: memory loss, headaches, muscles aches among survivors | Direct invasion Para-infectious—septic-related Para-infectious—secondary to metabolic dysfunction | Supportive care with early rehydration, correction of electrolyte disturbances and treating secondary infections |
| **Measles (measles virus)*** | Until 1963: massive global outbreaks every 2–3 years, until vaccine is developed, decreasing number of cases worldwide 2019–current: outbreaks in all regions of the world (increase in number of cases and resurgence in areas of Europe and USA in the last 10 years) | Direct contact with respiratory droplets and aerosolised particles from infected people and fomites. Aerosolised particles can remain in the air for up to 2 h | 7–14 days | Starts with high fever and one or more of the three symptoms: coryza, cough and conjunctivitis. Koplik spots (small white spots) appear in the mouth 2–3 days after start of symptoms. Maculopapular rash appears 3–4 days after the onset of symptoms | Acute Encephalitis (primary measles encephalitis) Acute post-measles encephalitis Measles inclusion-body encephalitis (MIBE) Subacute sclerosing panencephalitis (SSPE) ADEM | Direct invasion Post-infectious—persistent or latent infection Post-infectious—autoimmune | Supportive care in the cute phase. Acute post measles encephalitis can be treated with corticosteroids, intravenous IgG is a possible 2nd line treatment. MIBE treatment is supportive and ribavirin is reported as beneficial. SSPE patients receive palliative care and symptoms control |
| Disease (pathogen) | Event/distribution | Mode of transmission | Incubation period | Non-neurological features | Neurologic manifestations | Mechanism of neurological injury | Treatment |
|--------------------|--------------------|----------------------|------------------|---------------------------|--------------------------|-----------------------------|-----------|
| AIDS (human immuno deficiency virus-HIV) | 1981–current: global | Exchange of body fluids from infected people, including blood, breast milk, semen and vaginal secretions. The virus is also transmitted vertically during pregnancy and delivery | 2–6 weeks for the 1st acute infection symptoms 2–15 years until the development of AIDS | The acute infection presents as a flu-like illness with fever, sore throat, body rash, fatigue, myalgia and lymphadenopathy for 1–2 weeks. After years of chronic infection symptoms related to the immune system damage appear and are related to the opportunistic infections that ensue. They include weight loss, chronic diarrhoea, fever, skin lesions, and any other symptom related to organ damage associated with the opportunistic infections | Aseptic meningitis Subacute encephalitis Neurocognitive disorders Peripheral neuropathy GBS Vacuolar myelopathy Stroke Amyotrophic lateral sclerosis-like Myopathy Predisposes secondary infections due to reactivated viruses: Progressive multifocal leukoencephalopathy (PML) (JC virus), primary CNS lymphoma (Epstein-Barr virus), neurocryptococcosis (Cryptococcus neoformans), neurotoxoplasmosis (Toxoplasma gondii) | Direct invasion Pan-infectious—secondary to coagulopathy and vasculitis Post-infectious—autoimmune Post-infectious—persistent or latent infection (including secondary reactivation of other latent viruses) | Early initiation of ART against HIV is effective against both direct effects of the virus and complications secondary to opportunistic infections. It has also shown to slow progression of cognitive disorders associated with the disease. Treatment of peripheral neuropathy involves both alleviation of pain and prevent progression by either initiating ART or suspending ART-related peripheral neuropathy |
| Smallpox (Variola virus) | Endemic in Asia since Antiquity Endemic in Europe since eleventh century with various outbreaks 165AD: Antonine Plague—Rome 735–737: Japan sixteenth-seventeenth century: Americas—decimation of native populations eighteenth century: USA | Direct contact with fluids from patients’ sores, fomites and respiratory droplets from infected people | 7–19 days | After 2–4 days of fever, myalgia, headache, fatigue and eventual vomiting. An early rash on the tongue and mouth installs followed by generalised skin rash. It progresses to putstular rash around the 6th day, which then forms a crust and a scab. 3 weeks after the start of rash most scabs will have fallen off | Post-infectious encephalomyelitis Post-vaccinal encephalomyelitis | | Supportive care |
paralysis secondary to anterior myelitis, GBS and transverse myelitis [59]. The most common CNS manifestation is brainstem encephalitis, severely affecting the medulla and frequently evolving to cardiac dysfunction and neurogenic pulmonary oedema. Seizures may occur in children under two years. Myoclonic jerks are frequent in encephalitic cases. Up to one-fifth of children with severe neurological manifestations have sequelae, and only a quarter of those with brainstem encephalitis and cardiorespiratory failure have a full neurological recovery [20].

**Variant Creutzfeldt-Jakob (vCJD)**

Bovine spongiform encephalopathy (BSE) was first described in 1985 and peaked in 1992/1993. The first cases of vCJD in humans were described in 1995 in the UK [149], and were found to be caused by the BSE prion [26]. vCJD affects a younger age group when compared to sporadic CJD with a median onset age of 26 years in the UK and 36 years in France [15]. The incubation period may be as long as 15–20 years [27]. In the earliest phase of vCJD psychiatric features are prominent with depression, short-lived delusions and hallucinations being most common [15]. Over 60% of patients may have persistent painful sensory features which are frequently lateralised. The majority of patients present with cerebellar features 4 to 6 months after disease onset. Myoclonus is a late feature, occurring more 6 months after onset, and chorea, tremor and dystonia are also common at this stage. Oculomotor problems and complaints of diplopia may be present in half of patients [15]. All patients develop cognitive impairment (with initial symptoms being disorientation and poor memory) and eventually dementia. Progression to death occurs on average 14 months after disease onset.

**Direct or indirect contact with infected individuals**

**Influenza**

Influenza viruses can be divided in seasonal and pandemic. The seasonal influenza A viruses (H3N2 and H1N1) cause yearly epidemics, while pandemics of influenza are the consequence of cross-species transmission, followed by adaptation to humans [77]. The CNS is the most common site of extra-respiratory complication of influenza infections [77]. Febrile seizures and encephalopathy are the most frequent neurological manifestations, affecting predominantly children [137]. Other acute neurologic presentations include meningitis, encephalitis (including acute necrotising encephalopathy and acute haemorrhagic leukoencephalopathy), and an increased frequency of ischaemic stroke, all during the acute disease [11, 137]. Influenza may also be associated with Reye’s syndrome, an acute encephalopathy with...
| Disease               | Imaging                                                                 | Laboratory                                                                                      |
|----------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Plague [8, 34, 35, 82, 109, 158] | Only once case report in the literature, of paediatric plague with positive PCR in the CSF for *Y. pestis* (but negative culture), with normal MRI | CSF: moderate neutrophil pleocytosis, increased protein, low glucose. Lymphocytic pleocytosis and normal glucose have also been described in some patients. Bloods: neutrophilic leucocytosis |
| West Nile virus [29, 123, 131, 147] | Brain CT is usually normal. If present, Brain MRI abnormalities are more likely to be seen during the 1st week and include leptomeningeal enhancement, T2/FLAIR hyperintense lesions in periventricular areas, deep brain structures (thalami, basal ganglia, red nucleus, cerebral peduncle, substantia nigra) and mesial temporal lobes. DWI sequences may detect lesions before T2/FLAIR. Most AFP cases have normal images, but some may present with abnormalities in the anterior horn and roots. | CSF: pleocytosis, which can be neutrophilic or lymphocytic, normal glucose and elevated protein in encephalitis or meningitis. Similar findings in AFP but with raised protein levels. Bloods: leucocytosis, elevated AST, ALT and serum lipase are commonly described. |
| Japanese encephalitis [131, 140, 145] | CT: bilateral thalamic hypodensities, which may be haemorrhagic and only visualised in the MRI. MRI changes include hyperintense lesions of thalamus, midbrain, pons, cerebellum, basal ganglia and cerebral cortex. | CSF: usually lymphocytic pleocytosis (though it can be acellular), normal protein and glucose levels. Blood: neutrophilia and hyponatraemia are frequent. |
| Zika virus [7, 90, 93, 94, 105] | Brain MRI abnormalities of symptomatic congenital Zika syndrome affects both white and grey matter and include: severe microcephaly, ventriculomegaly, skull collapse, fluid grey-matter interface calcifications, corpus callosum anomalies, cerebral cortex thinning, abnormal gyral patterns, pontine atrophy, cerebellum hypoplasia, choriotinal atrophy, microphthalmia, cataracts and optic nerve atrophy. Neuroimaging of encephalitic adult cases in non-specific and can be normal. Most commonly reported findings are asymmetric subcortical T2/FLAIR hyperintense lesions (also seen in DWI). | CSF: moderate pleocytosis and mildly raised protein, with mostly normal glucose in meningoencephalitis. In GBS, usually normal WBC and increased protein levels. Blood: leukopenia, thrombocytopenia, increase transaminases levels. |
| Chikungunya fever [19, 41, 42, 86, 146] | Brain CT and MRI can be normal even in encephalitic cases. Both imaging modalities can show unspecific oedema and haemorrhage in different areas of the cerebrum during the acute phase. ADEM cases present with typical confluent areas of T2/FLAIR hyperintensity consistent with demyelination. Myelopathic patients have spinal cord T2/FLAIR hyperintense lesions in the affected segment. | CSF: pleocytosis (although it can be very modest or normal) and raised protein in meningoencephalitis and myeloradiculitis. Blood: lymphopenia (almost always present), thrombocytopenia, elevated AST and ALT and hypocalcaemia. |
| Malaria [78, 107, 111, 153] | Brain imaging findings do not correlate with parasitaemia, and can be normal. CT may display vasogenic oedema specially involving the posterior brain, ischaemic hypodensities in thalamus and cerebellar white matter. Brain MRI shows non-specific T2WI hyperintensities in the thalamus, periventricular white matter, corpus callosum, occipital sub-cortex and basal ganglia. | CSF: very mild pleocytosis, low glucose and increased protein levels. Blood: Anaemia, hyperbilirubinemia (due to haemolysis), thrombocytopenia, haemoglobinuria and elevated transaminases are usually present in a range of severities. Young children and pregnant women may have hypoglycaemia and metabolic acidosis. |
| Yellow fever [85, 89] | There’s a paucity of MRI studies in yellow fever-related encephalitis. Case reports have described lesions associated with the rare complication of yellow fever 17D vaccination with unspecific T2WI hyperintense lesions in cerebral peduncles, medulla, spinal cord and cerebral white matter. | There’s scarce information about CSF in yellow fever in the literature. Bloods: leukopenia (with relative neutropenia), thrombocytopenia, elevated aminotransferases and bilirubin levels, increased prothrombin time (PT), albuminuria. |
Table 3 (continued)

| Disease                          | Imaging                                                                 | Laboratory                                                                 |
|----------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Dengue fever [17, 49, 129]       | Brain CT may reveal intraparenchymal foci of haemorrhages. Brain MRI of meningoencephalitis frequently shows hyperintensity on T2WI and DWI in both thalami, basal ganglia, cortical grey matter and subcortical white matter. Petechial haemorrhages and diffuse brain oedema are common | CSF: frequently normal in most encephalitic cases. Modest lymphocytic pleocytosis with normal or raised protein levels may be present in dengue myelitis, encephalitis or meningitis. Blood: leukopenia, thrombocytopenia and rising haematocrit |
| Poliomyelitis [38, 58, 63, 81]   | MRI show T2W hyperintense ventral motor tracts both in the spinal cord and in the motor cortex | CSF: pleocytosis (neutrophilic in the 1st days which then progresses to lymphocytic), mildly elevated protein levels and normal glucose in the acute phase |
| Enterovirus-71 [59, 67, 100, 125, 130, 133] | In encephalitic patients, brainstem is the most affected site. Brain MRI shows T2W hyperintense in the midbrain, dentate nuclei, dorsal aspect of the pons (pontine tegmentum), basal ganglia and medulla. Usually there’s no supratentorial involvement | CSF: mild lymphocytic pleocytosis (though it may be normal), and usually normal protein and glucose levels in acute encephalitic patients. Bloods: leucocytosis, mainly neutrophilic, especially in those with central involvement |
| Variant Creutzfeldt-Jakob disease [15, 88] | Brain MRI of most cases of vCJD show the characteristic “pulvinar sign”—an area of high signal in T2W in the posterior thalamus rather than any other area. Other areas which may be involved include dorsomedial thalamic nuclei and the periaqueductal grey matter. Hyperintensities in T2W and DWI in the caudate, putamen and cortical areas, characteristically involved in sCJD, may also affected vCJD patients. | CSF: usually normal, sometimes with modest total protein elevation. CSF 14-3-3 is positive only in half of vCJD patients |
| Influenzae [1, 18, 30, 44, 51]   | Encephalitic patients may present with normal imaging. Specific encephalitic syndromes have been described in those patients, divided in splenial sign (T2 and DWI high signal in the splenium of corpus callosum); ANE-pattern (acute necrotising encephalitis—hyper signal in T2WI in thalami, midbrain, pons, cerebellum, centrum semiovale); PRES pattern (hyperintense signal in T2WI in centrum semiovale, more prominent posteriorly); malignant brain oedema (diffuse brain oedema). Post infectious cerebellitis displays T2WI hyperintense images in the cerebellum, with brainstem compression and hydrocephalus. Encephalitis lethargica patients presented with loss of neurons in the midbrain, subthalamus and hypothalamus. Post viral parkinsonism subjects had depigmentation of the substantia nigra and locus coeruleus. | CSF: normal or with pleocytosis, proteins frequently elevated, normal glucose, in encephalitic cases. Bloods: variable, may be closer to normal. Frequent lymphocytopenia, thrombocytopenia, elevated AST, CRP |
| Disease                  | Imaging                                                                 | Laboratory                                                                 |
|-------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------|
| **Coronavirus [55, 66, 70, 102, 162, 163, 165]** | While there’s scarce information about brain images of patients infected with SARS-CoV1 and MERS-CoV, recent studies have reported varied lesions in patients with neurologic manifestations secondary to SARS-CoV2 and novel information comes up every day. Within the plethora of described lesions, the most frequently reported are SWI abnormalities (with ovoid or tubular shape) affecting mainly the splenium, juxta cortical U-fibres and main white matter tracts, non-confluent white matter hyperintense lesions on T2WI and DWI associated or not with haemorrhagic lesions and often involving corpus callosum and middle cerebellar peduncles, symmetric thalamic lesions with oedema, petechial haemorrhage and necrosis compatible with ANE (with variable extension to the brainstem, cerebral and cerebellar white matter tracts). Other described lesions include prominence of optic nerve subarachnoid spaces, sign abnormalities in the medial temporal lobe and olfactory bulb, contrast enhancement of intraparenchymal lesions, leptomeninges and cranial nerves. Some patients also developed T2WI hyperintensities in the periventricular areas and spinal cord, suggestive of demyelination, and ADEM-compatible lesions in COVID-19 patients have been described. | CSF: normal or with pleocytosis, with variable degrees of proteinorraquia and generally normal glucose. Bloods: variable. Frequent findings are lymphopenia, decreased eosinophils, decreased albumin, raised CRP, increased LDH and increased interleukin-6. |
| **Ebola [10, 21, 22, 60, 80, 115]** | Patients with presumed Ebola meningoencephalitis are rarely scanned. Case reports have described punctate T2WI hyperintense lesions in the subcortical white matter, corpus callosum and peri fourth ventricle, compatible with microvascular lesions. | CSF: few case reports, evaluated only to detect viruses’ genetic material. Bloods: leukopenia (earlier in the disease) or leucocytosis, thrombocytopenia, elevated transaminases (AST > ALT). Electrolyte disturbances with the disease-associated volume loss: hypo/hypernatremia, hypokalaemia, hypocalcaemia and hypomagnesemia. Coagulation abnormalities may occur. |
| **Measles [6, 16, 39, 47, 74, 124]** | In the acute phase and acute post-measles encephalitis, brain MRI shows multifocal hyperintense T2WI in both cerebral hemispheres, involvement of dorsal striatum and cortex oedema. MIBE presents with T2WI and DWI hyperintense lesions in the brainstem, cerebellum, multifocal cortical and subcortical grey matter lesions (including basal ganglia and thalamus), without contrast enhancement. SSPE has a progressive course, initially with patchy asymmetric hyperintense lesions in T2WI in the white matter of both parietal and temporal lobes. It progresses to involve the corpus callosum and basal ganglia, culminating with generalised encephalomalacia. | CSF: acute encephalitis and acute post-measles encephalitis: lymphocytic pleocytosis with high protein and mildly low glucose. MIBE—CSF is usually normal, but may present with pleocytosis and elevated protein. SSPE—only high titres of measles antibody. Bloods: Leukopenia, thrombocytopenia and T cell cytopenia during the acute infection. |
HIV-associated encephalopathy usually presents with symmetric T2WI hyperintense lesions affecting mainly periventricular and deep white matter, with associated encephalomalacia, with no mass effect or enhancement. HIV-associated cerebral vasculopathy may lead to multiple nodular and fusiform aneurysms of large and medium arteries which can cause subarachnoid or intraparenchymal haemorrhages or embolic infarcts. HIV-related vacuolar myelopathy presents with spinal cord atrophy (mainly at the thoracic level, but cervical cord may be affected) with frequent bilateral symmetric dorsal column involvement.

CNS opportunistic infections in AIDS patients have characteristic dependent of its agent, the most common being:

- Neurotoxoplasmosis typically causes nodular lesions in the basal ganglia and at the corticomedullary junction with 1–3 cm and perilesional oedema. Brain MRI shows concentric alternating zones of hypointense and isointense in T2WI with post contrast ring enhancement.

- CMV encephalitis shows non-specific T2WI hyperintensities in the periventricular white matter with no mass effect and no enhancement.

- cryptococcosis usually leads to lesions with little enhancement, spread along perivascular spaces mostly in the basal ganglia and white matter of cerebral hemispheres, brainstem and cerebellum. Dilated perivascular spaces can coalesce into gelatinous pseudocysts ("soap bubble") with high signal in T2WI. Cryptococcomas are usually T2WI hyperintense nodular lesions in the cerebral parenchyma with variable enhancement. The meningeal disease usually shows leptomeningeal and pachymeningeal enhancement.

- PML is typically multifocal and asymmetric with periventricular and subcortical demyelinating lesions, especially subcortical U-fibres in the parieto-occipital areas. Multiple punctate high T2 signal lesions around the involved area ("milky way sign") differentiate it from multiple sclerosis lesions.

- CNS lymphoma classically presents as supratentorial mass lesions which are T1 hypointense, T2 isointense with high signal in DWI and homogeneous enhancement with subependymal extension and crossing of the corpus callosum.

Cholera was not included in this table as its neurological manifestations are related solely to metabolic disturbances and no structural changes in the brain imaging or CSF are described.
mitochondrial dysfunction and hepatic metabolic failure, triggered by drugs (especially aspirin) [121].

Late post infectious neurological complications of influenza have been extensively reported and are more frequent in adults. These include including GBS, cerebellitis, Kleine-Levin syndrome, myositis and transverse myelitis [137, 150]. A link between encephalitis lethargica (von Economo disease) and influenza A has been suggested with an outbreak of encephalitis lethargica cases noted after the 1918 Influenza pandemic [56]. During the acute phase, patients presented with excessive sleepiness, disorders of ocular motility, fever and movement disorders; frequently preceded by flu-like symptoms. The chronic phase typically developed 1–5 years after acute disease, but has been delayed by up to 45 years. Symptoms include Parkinsonism with psychiatric symptoms, abnormal ocular movements, speech abnormalities, spasticity and brisk reflexes; a constellation of symptoms memorably described by the neurologist Oliver Sacks in his book “Awakenings” [114]. There remains controversy whether encephalitis lethargica is caused by direct CNS invasion by the influenza virus, or represents a virus-related autoimmune phenomenon [56]. Other cases of post-encephalitic Parkinsonism not related to encephalitis lethargica have been reported after influenza infections [61].

Coronaviruses

Since the beginning of the twenty-first century three coronaviruses (CoV) have been responsible for pandemics; severe acute respiratory syndrome (SARS-CoV1) in 2003, Middle East respiratory syndrome (MERS-CoV) in 2012 and SARS-CoV2 (also known as COVID-19) in 2019. Most human coronaviruses cause only mild respiratory symptoms and four strains are endemic worldwide, responsible for up to one third of upper respiratory tract infections in immunocompetent individuals: HCoV-229E, -OC43, -NL63 and -HKU1 [32].

Coronaviruses can invade the CNS and have been associated with many neurological sequelae including demyelinating diseases [4], optic neuritis [33], and Parkinson disease [37]. HCoV-OC43 was linked to a case of ADEM [160], fatal encephalitis in an immunodeficient child [91], and to a subset of Chinese children with encephalitis [75].

SARS-CoV1

The 2002–2003 pandemic affected > 8000 people in 30 countries, 10% of whom died [71]. SARS-CoV1 was found in CSF samples and brain tissue of encephalopathic patients with symptoms including seizures [72] and optic neuritis, manifesting in the acute phase [157]. Large artery ischaemic stroke were reported in 2.4% [141]. Neuromuscular disorders including myopathy and axonal motor neuropathy were reported among critically ill patients, later during the course of the disease. However, it is not clear whether this is a consequence of direct viral CNS infection, the host inflammatory response, and/or immunologic processes [139].

MERS-CoV

MERS has been an ongoing pandemic since initial reports in 2012 and has already affected > 2500 people, 35% of which died [155]. In Saudi Arabia, seizures were reported during the acute phase, in > 8% of patients and confusion in > 25% [113]. ADEM, encephalitis and stroke (possibly due to vasculitis) have also been described [3]. Notably none of these conditions had MERS-CoV detected in CSF. A Korean study reported Bickerstaff’s brainstem encephalitis and polyneuropathy among patients with MERS in the first few weeks of infection [64].

SARS-CoV-2

In December 2019, a new coronavirus appeared in Wuhan, China. A large current worldwide pandemic has resulted in six million recorded cases and over 1 million deaths, as of end of September 2020 [62]. Neurological complications of the disease have been reported and its mechanisms are still being scrutinised by the scientific community [36]. A retrospective Chinese study with 214 hospitalised patients described neurological features in just over one third of cohort, including dizziness, headaches and impaired consciousness [83]. A French cohort of 58 critically ill patients reported encephalopathy and corticospinal signs. Brain MRI was performed in 13 patients, 8 of whom had leptomeningeal enhancement and 2 had acute ischaemic lesions [55]. There are reports of COVID patients with rhombencephalitis [151] and meningoencephalitis [159], some with positive Sars-CoV2 in the CSF [92], most of which presented with seizures and encephalopathy. Acute haemorrhagic leukoencephalitis [108], demyelinating lesions [162], ADEM [102] and acute myelitis have also been reported [2]. Peripheral nervous system manifestations include anosmia/ageusia in over 80% of infected [73], GBS (both demyelinating and axonal) [138], Miller-Fisher syndrome (MFS) and isolated abducens palsies [48]. An increased frequency of acute cerebrovascular events among COVID patients is reported [101], at a similar frequency to previous studies of patients with sepsis [12]. This may be the consequence of a hypercoagulable state [164] related either to the viral infection or to the host response [97].

There are increasing reports of many patients suffering from a long-term syndrome lasting more than 3 months post infection which has been badged as “long COVID.” Neurological-type symptoms including neurocognitive difficulties, depression and other mental health conditions, peripheral
neuropathies and muscular weakness [46]. This is distinct from critical illness acquired weakness, and the neurocognitive sequelae described in post intensive care syndrome [9], as the majority of the patients reporting this syndrome have not been hospitalised.

**Ebola**

First described in 1976, Ebola has caused several outbreaks, mainly in African countries, the largest in 2014–2016. Neurological complications begin in the late stage when patients can have encephalopathy, seizures (probably due to metabolic abnormalities), meningitis and meningoencephalitis [21]. The exact prevalence of neurological complications in the acute phase is unknown. The CNS may be a reservoir for Ebola virus; it was recovered from the CSF (at higher levels than the blood) of an Ebola survivor 9 months after the patient’s recovery, when it then developed meningoencephalitis and radiculitis [60]. Long-term neurological sequelae are not uncommon among survivors, with memory loss in up to 40%, headaches in one third and muscle pain in 13% [128].

**Measles**

Until the introduction of attenuated measles vaccine, the disease killed 2–3 million people/year [154]. The mortality associated with measles decreased steadily since widespread vaccination programs were put in place in the beginning of the twenty-first century. However, since 2016, declining vaccination rates have resulted in epidemics in all WHO regions, including in previously measles-eradicated areas, like USA and Western Europe [104]. Though pneumonia is the main cause of death, severe CNS manifestations may occur. Primary measles encephalitis (PME) manifests during the exanthem due to direct CNS invasion with seizures, disturbances of consciousness and focal signs. Up to 15% of such patients die and a quarter have permanent neurological damage [16]. The most frequent CNS complication of measles is acute post measles encephalitis, which occurs 2–30 days after infection and affects around 0.1% of children after a measles infection. Another complication is measles-induced ADEM, which begins weeks or months after rash clearance [16, 47]. Prognosis is better than with PME. Measles inclusion body encephalitis (MIBE) is another complication, in which a progressive measles virus brain infection affecting patients with impaired cellular immunity, manifesting within 1 year of the primary infection. It presents as altered consciousness, refractory seizures and focal signs. Mortality is 75% [16, 47]. Subacute sclerosing panencephalitis (SSPE) manifests 4–15 years after an acute measles infection, with a higher incidence in children who had the disease before the age of 5 [47]. SSPE is caused by persistence of a mutant measles virus after failure to completely clear the primary infection, and manifests initially as behavioural changes and cognitive decline, followed by myoclonic jerks, dyskinesias and ataxia, progressing to coma and death [16, 47]. Measles vaccination reduces SSPE incidence.

**HIV/AIDS**

Since the beginning of the pandemic in the 1980s, 75 million people have been infected with HIV, and 32 million have died [152]. While the introduction of combined antiretroviral therapies (cART) has decreased mortality and morbidity of acquired immunodeficiency syndrome (AIDS) and opportunistic infections (OI), the prevalence of complications associated with long-term HIV infections and its treatment have increased, particularly the neurologic ones [95]. Acute HIV infection can cause headache and neck stiffness secondary to aseptic meningitis [119].

The most common CNS OI are tuberculous meningoencephalitis, neurotoxoplasmosis, cryptococcal meningitis, cytomegalovirusis and progressive multifocal leukoencephalopathy (PML) secondary to JC virus [95]. Others include primary CNS lymphoma (associated with Epstein-Barr virus) and varicella-zoster vasculitis, with encephalopathy, cranial nerves palsies, strokes and seizures [119].

Immune reconstitution inflammatory syndrome (IRIS) may occur weeks to months after recovery from an immunodeficient state. Low CD4 before initiation of cART is the strongest predictor of IRIS. It can affect any organ and CNS-IRIS prevalence is around 1%, occurring in response to dying opportunistic agents (frequently linked to Cryptococcus or PML) or as a fulminant encephalitis associated with CD8+ T cells infiltration [95].

Up to 50% of HIV patients may be affected by HIV-associated neurocognitive disorders (HAND) which range from asymptomatic to dementia [52]. HAND is a subcortical cognitive disorder and presents with psychomotor retardation, executive dysfunction, deficits of working memory, retrieval, judgment, attention and impulse control, manifesting as a long-term complication of the infection. In the cART-era the incidence of HIV-related dementia has decreased to under 5% [95]. HIV disease markers are no longer closely related to cognitive impairment [50], and patients receiving cART have a better cognitive performance than patients who are cART-naïve [52]. This indicates that the pathophysiology of cognitive impairment may be related to the inflammatory process which occurs in the presence of the virus in the CNS.

HIV infection can lead to a distal symmetric polyneuropathy, which can be related both to neurotoxic antiretrovirals and to the viral infection per se, affecting small fibres and causing numbness and painful distal limbs symptoms. Polyneuropathy affects 30–70% of HIV patients and
immunosuppression no longer predicts its severity [103]. It may be related to neurotoxicity secondary to viral replication or to an immune reconstitution mechanism, damaging peripheral nerves and usually manifests in the chronic phase of the disease [95]. GBS (mainly demyelinating) has been associated with HIV very early in the infection [54].

HIV is independently associated with increased risk for stroke which may be secondary to viral effects on endothelial dysfunction, vascuropathy and hyperviscosity [103]. Protease inhibitors used as antiretrovirals may also have a negative effect on vascular endothelial function.

Vacuolar myelopathy manifests in chronic AIDS [119]. An amyotrophic lateral sclerosis-like syndrome has been reported, and may resolve resolved after initiation of cART [95, 119]. Myopathy can occur regardless of the course of HIV infection, and is associated with direct virus lesion, inflammatory response, or ART (zidovudine) [95].

Other diseases and potential threats

Increases in global temperatures and a changing climate can lead to environmental adaptations of benefit for various disease vectors, including mosquitoes. These are the key vector for malaria, whose epidemic potential should increase in susceptible tropical countries (extending to highland areas) that had controlled the disease or be reintroduced in temperate climates that had previously eliminated it. The most severe form of malaria (and cause of 500,000 deaths per year) is cerebral [107], affecting mainly young children during the acute illness.

Yellow fever, another mosquito-borne virus, was a major threat to human health until the beginning of the twentieth century, having caused multiple epidemics and deaths in cities distant from endemic areas, in North America, the Caribbean and Europe [89]. The expansion of the disease to non-endemic areas means that susceptible non-vaccinated populations are now prone to new epidemics. The virus can rarely invade the CNS and cause encephalitis and meningitis early in the course of infection. Encephalopathy is also common in the context of hepatic failure of severe forms of the disease. Though extremely rare, yellow fever vaccine-associated neurotropic disease is reported, causing encephalitis, GBS and ADEM [89].

The mosquito-borne dengue virus has expanded from a sporadic disease affecting 9 countries in the 1970s to being endemic in over 100 countries; half of the world is now at risk. Neurological complications can occur at any stage. Dengue encephalopathy is the most common and involves impaired consciousness in the context of shock, liver failure and electrolyte disturbances in the first 10 days of the disease. Meningitis and encephalitis due to CNS invasion of the virus are also possible, though rare, and patients present with decreased level of consciousness, headache, dizziness, seizures and focal signs, also in the acute phase. Post-dengue immune-mediated complications include GBS, transverse myelitis, ADEM, mononeuropathies of cranial nerves, optic neuropathy, muscle dysfunction and intracranial haemorrhages during the convalescence stage [17].

War, conflicts and natural disasters can facilitate the spread of diseases like cholera. Cholera has caused seven pandemics in the last two centuries. Electrolyte disturbances and hypoglycaemia (mainly in children) secondary to severe diarrhoea and acute dehydration can lead to symptomatic seizures [23]. Concurrent outbreaks of cholera and peripheral neuropathies have been described among undernourished displaced populations, in the subacute phase of the disease [112].

The recent decrease in coverage of MMR (measles, mumps and rubella) vaccine in some areas has also led to an increase of cases of rubella and mumps. Mumps can cause aseptic meningitis and encephalitis in the early days of the disease and ADEM as a late post infectious complication [6]. The major neurological manifestation of rubella is the congenital rubella syndrome (CRS) in foetuses whose mothers are infected during pregnancy. CRS includes causes encephalopathy, microcephaly and sensorineural hearing loss. Encephalitis has also been reported during the exanthematic phase [6].

Smallpox was a cause of massive epidemics until its eradication in the 1980s by global immunisation programs. Since most of people living today are not vaccinated against it and the viable variola virus is still kept in two maximum security laboratories [87], it is feared that it could be used in bioterrorist attacks. Neurological complications of smallpox were uncommon and have been poorly studied, but descriptions are compatible with demyelinating/inflammatory encephalomyelitis, 5 to 16 days after the acute disease [13]. Post-vaccination encephalomyelitis has also been described, mainly in young children [13].

Conclusion: preparing for the future

Pandemics and epidemics have been present for thousands of years, and have played a pivotal role in history. Much of previous focus has been on the acute illnesses themselves, with relatively little attention paid to the social, human and economic consequences of neurological sequelae. However, it is these sequelae that often lead to significant amounts of mortality and long-term morbidity.

Under-recognition of neurological manifestations means that few studies have been conducted in previous pandemics to understand, treat and prevent neurological complications, and so the burden of secondary complications is even greater. With the recent developments in imaging, new
information about the presentation of CNS diseases is available and can assist in the proper diagnosis of neurologic manifestations of infectious diseases. However, even in developed countries, diagnostic tests are limited and treatments are often inadequate or non-existent, with significant long-term economic and healthcare consequences. Therefore, it is reasonable to expect that in low and middle-income countries with poorer access to diagnostic tests and treatments, the neurological involvement by these diseases will have a greater economic impact. Potentially limiting future human capital by leaving long-term motor and cognitive impairments.

This urgent need to pay more attention to the short- and longer term sequelae of pandemics has been brought into sharp focus with COVID-19 where there have been numerous reports of short-term sequelae and a growing appreciation of longer term problems. There is a growing recognition of the need to work globally with international collaborations being formed to better understand the neurological consequences of COVID-19 [53]. These include (but are not exclusive to) the CoroNerve Study Group [143], European Academy of Neurology’s EAN Neuro-COVID Registry Consortium (ENERGY) [98], and the Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID) [40].

However, it is also important to learn from previous pandemics to understand what to expect and plan responses to improve the outcomes. This knowledge of what has occurred in the past is useful to highlight symptoms and signs to be vigilant for ensuring such sequelae are not missed. For example, encephalitis lethargica and post-encephalitic Parkinsonism have been seen after viral infections, most notably the 1918–19 influenza pandemic [43]. Indeed, a case of Parkinsonism in a patient post COVID-19 has been described, including a reduction of 18F-fluorodopa uptake bilaterally in the putamina [25]. In the months to years following this pandemic it would be important to continue to look for such patients.

As new infections continue to emerge, new pandemics will certainly happen. Despite advances in the treatment of infectious diseases in the last century, those affecting the nervous system are still challenging. An improved understanding of the pathophysiology of neurologic damage and recognising its possible manifestations is fundamental to develop new treatments and management strategies.

Neurological involvement in pandemics and epidemics is common and can cause devastating consequences amongst affected populations. There is an urgent need for better address this issue in pandemics, including the current SARS-CoV-2 outbreak.

Acknowledgements DW was supported by an Academic Clinical Fellowship. DKM was supported by the NIHR through the NIHR Cambridge Biomedical Research Centre grant and a Senior Investigator Award. VFJN was supported by an Academy of Medical Sciences/The Health Foundation Fellowship.

Author contributions FV and VFJN conceived the idea. FV performed the literature review and initial draft. All authors contributed substantially to the writing of the manuscript.

Funding DW was supported by an Academic Clinical Fellowship. DKM was supported by the NIHR through the NIHR Cambridge Biomedical Research Centre grant and a Senior Investigator Award. VFJN was supported by an Academy of Medical Sciences/The Health Foundation Fellowship. No funding source had any role in the writing of this manuscript and decision to submit for publication.

Compliance with ethical standards

Conflicts of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Akins PT, Belko J, Uyeki TM, Axelrod Y, Lee KK, Silverthorn J (2010) H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care 13:396–406
2. AlKetbi R, AlNuaimi D, AlMulla M, AlTalai N, Samir M, Kumar N (2020) Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings. Radiol Case Rep 15(9):1591–1595
3. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, Saeed BT, Wahbi A, Saedy A, AlDabbagh T, Okaili R, Sadat M, Balkhy H (2015) Severe neurologic syndrome associated with Middle East respiratory syndrome coronavirus (MERS-CoV). Infection 43:495–501
4. Arbour N, Day R, Newcombe J, Talbot PJ (2000) Neuroinvasion by human respiratory coronaviruses. J Virol 74:8913–8921
5. Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. Am J Neuroradiol 31:1564–1576
6. Bale JF Jr (2014) Measles, mumps, rubella, and human parvovirus B19 infections and neurologic disease. Handb Clin Neurol 121:1345–1353
7. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D (2017) An update on Zika virus infection. Lancet 390:2090–2109
8. Becker TM, Poland JD, Quan TJ, White ME, Mann JM, Barnes AM (1987) Plague meningitis–a retrospective analysis of cases reported in the United States, 1970–1979. West J Med 147:554–557
9. Biehl M, Sese D (2020) Post-intensive care syndrome and COVID-19 — Implications post pandemic. Clevel Clin J Med. https://doi.org/10.3949/ccjm.87a.ccc055
10. Billious B, Smith B, Nath A (2016) Neurological complications of Ebola virus infection. Neurotherapeutics 13:461–470
11. Boehme AK, Luna J, Kulick ER, Kamel H, Elkind MSV (2018) Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neuro 5:456–463
12. Boehme AK, Ranawat P, Luna J, Kamel H, Elkind MS (2017) Risk of acute stroke after hospitalization for sepsis: a case–cross-over study. Stroke 48:574–580
13. Booss J, Davis LE (2003) Smallpox and smallpox vaccination: neurological implications. Neurology 60:1241–1245
14. Boulanger LL, Ettestad P, Fogarty JD, Dennis DT, Romig D, Mertz G (2004) Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985–1999. Clin Infect Dis 38:663–669
15. Brandel JP, Knight R (2018) Variant Creutzfeldt-Jakob disease. Handb Clin Neurol 153:191–205
16. Buchanan R, Bonthius DJ (2012) Measles virus and associates. Lancet Neurol 11:976–986
17. Carod-Artal FJ, Wichmann O, Farrar J, Gascón J (2013) Neurological complications of dengue virus infection. Lancet Neurol 12:906–919
18. Casals J, Elizan TS, Yahr MD (1998) Postencephalitic parkinosis—a review. J Neurol Transm (Vienna) 105:645–676
19. Cerny T, Schwarz M, Schwarz U, Lemant J, Gérardin P, Keller E (2017) The range of neurological complications in Chikungunya fever. Neurocrit Care 27:447–457
20. Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, Lin TY (2007) Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 356:1226–1234
21. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Spreen W, Menon D, McNett M, Suarez JI, Helbok R, McNett M, A’Court C, Buxton M, Husain L (2020) Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale. Neurocrit Care 33:25–34
22. Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, Bishop RJ, Childs RW, Arai AE, Palmore TN, Lane HC, Fauci AS, Davey RT (2016) Severe meningoencephalitis in a case of Ebola virus disease: a case report. Ann Intern Med 165:302–304
23. Clemens JD, Nair GB, Ahmed T, Quadri F, Holmgren J (2017) Cholera. The Lancet 390:1539–1549
24. Clifford DB, Ances BM (2013) HIV-associated neurocognitive disorder. Lancet Infect Dis 13:976–986
25. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ishpsha M, Bar-Shalom P, Rickert RH, Gayer H, Skrahna V, Bornstein NM, Yahalom G (2020) A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol 19:804–805
26. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383:685–690
27. Cousins SN, Vynnycky E, Zeidler M, Will RG, Smith PG (1997) Predicting the CJD epidemic in humans. Nature 385:197–198
28. Dando SJ, Mackay-Sim A, Norton R, Currie BJ, St. John JA, Ekberg JAK, Batzloff M, Ulett GC, Beckham IR (2014) Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev 27:691–726
29. Davis LE, De Biasi R, Goade DE, Haaland KY, Harrington JA, Harnar SB, Pergam SA, King MK, DeMasters BK, Tyler KL (2006) West Nile virus neuroinvasive disease. Ann Neurol 60:286–300
30. Davis LE, Koster F, Cawthon A (2014) Neurologic aspects of influenza viruses. Handb Clin Neurol 123:619–645
31. de Araujo TVB, Rodrigues LC, de Alencar Ximenes RA, de Barros M-F, Montarroyos UR, de Melo APL, Valongueiro S, de Albuquerque M, Souza WV, Braga C, Filho SPB, Cordeiro MT, Vazquez E, Cruz DCS, D, Henriques CMP, Bezerra LCA, da Silva Castanha PM, Dhalia R, Marques-Júnior ETA, Maretelli CMT, (2016) Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study. Lancet Infect Dis 16:1356–1363
32. Desforges M, Le Coupacel A, Dubeau P, Bourgoin A, Lajoie L, Dubé M, Talbot PJ (2020) Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 12:14
33. Dessau RB, Lisby G, Frederiksen JL (1999) Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 100:88–91
34. Drummond WK, Nelson CA, Fowler J, Epson EE, Mead PS, Lawaczek EW (2014) Plague in a pediatric patient: case report and use of polymerase chain reaction as a diagnostic aid. J Pediatric Infect Dis Soc 3:e38–e41
35. Greenhalgh T, Knight M, A’Court C, Buxton M, Roberts R, Roberts M, Carrol ED, Lim M, Avula S, Solomon T, Kneen R (2014) Neurological manifestations of influenza infection in children and adults: results of a National British Surveillance Study. Clin Infect Dis 58:775–784
36. Griffin DE (2014) Measles virus and the nervous system. Handb Clin Neurol 123:577–590
37. Gérardin P, Couderc T, Bintner M, Tournebize P, Renouil M, Lecuit M, Michault A, Encephalchik Study Group (2016) Chikungunya virus-associated encephalitis: a cohort study on La Réunion Island, 2005–2009. Neurology 86(1):94–102. https://doi.org/10.1212/WNL.0000000000002234
38. Giordano A, Schwarz G, Cacciaguerra L, Esposito F, Filippi M (2020) COVID-19: can we learn from encephalitis lethargica? Lancet Neurol 19:570
39. Goenka A, Michael BD, Ledger E, Hart IJ, Absoud M, Chow KL, Harnar JB, Pergam SA, King MK, DeMasters BK, Tyler KL, Lawaczeck EW (2014) Plague in a pediatric patient: case report and use of polymerase chain reaction as a diagnostic aid. J Pediatric Infect Dis Soc 3:e38–e41
48. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, de Aragón-Gómez F, Benito-León J (2020) Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. https://doi.org/10.1212/WNL.0000000000009619

49. Guzman MG, Harris E (2015) Dengue. Lancet 385:453–465

50. Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe 49. Guzman MG, Harris E (2015) Dengue. Lancet 385:453–465

51. Hayase Y, Tobita K (1997) Probable post-influenza cerebellitis. Intern Med 36:747–749

52. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kum- helbok R, Chou SH-Y, Beghi E, Mainali S, Frontera J, Robertson 57. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, helmy-dia G, Benzakoun J, Oppenheim C, Bapst B, Megdiche I, Henri- 58. Howard RS (2005) Poliomyelitis and the postpolio syndrome. Hotchkiss RW, Lepage M, Rosner A, Caramori G, Wanner H, 59. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF 60. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropsey I, Filipe A, Slike B, Prueksakaew P, Jagodzinski LL, Puttamaswin S, Park SS, Park TH, Ahn JY, 61. Coronavirus Resource Center - John Hopkins University and 62. Coronavirus Resource Center - John Hopkins University and 64. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, Ahn JY, Kim MK, Choi JP (2017) Neurological complications during 65. Klein RS, Garber C, Howard N (2017) Infectious immunity in the central nervous system and brain function. Nat Immunol 18:132–141

66. Klironomos S, Tzortzakakis A, Kits A, Öhberg C, Collia A, Ahor- romazdae A, Almqvist H, Aspelin A, Martin H, Ouellette R, Al-Saadi J, Hasselberg M, Haghgo M, Pedersen M, Petersson T, Finnsson J, Lundberg J, Falk Delgado A, Granberg T (2020) Nervous system involvement in COVID-19: results from a retrospective consecutive neuroimaging cohort. Radiology. https://doi.org/10.1148/radiol.202022791

67. Komatsu H, Shimizu Y, Takeuchi Y, Ishiko H, Takada H (1999) Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol 20:17–23

68. Koyuncu OO, Hogue IB, Enquist LW (2013) Viruses infections in the nervous system. Cell Host Microbe 13:379–393

69. Kramer LD, Li J, Shi PY (2007) West Nile virus. Lancet Neurol 6:171–181

70. Kremer S, Lersy F, de Séze J, Ferré JC, Maamur A, Carsin-Nicol 71. infection. N Engl J Med 341:936–942

72. Kremer S, Lersy F, de Séze J, Ferré JC, Maamur A, Carsin-Nicol 73. virus disease (COVID-19): a multicenter European study. Eur 74. Kuemmerlen C, Ferriéres D, Marquet A, Marchant D, Brouard 75. Li Y, Li H, Fan R, Wen B, Zhang J, Cao X, Wang C, Song Z, Li 76. Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children. Intervirology 59:163–169
76. Lo JK, Robinson LR (2018) Post-polio syndrome and the late effects of poliomyelitis: Part 2. treatment, management, and prognosis. Muscle Nerve 58:760–769
77. Ludlow M, Kortekaas J, Herden C, Hoffmann B, Tappe D, Trebst C, Griffin DE, Brindle HE, Solomon T, Brown AS, van Riel D, Wolthers KC, Pajkrt D, Wohlsiepen P, Martina BEE, Baumgartner W, Verjans GM, Osterhaus ADME (2016) Neurotropic viruses infections as the cause of immediate and delayed neuropathology. Acta Neuropathol 131:159–184
78. Luzolo AL, Ngoyi DM (2019) Cerebral malaria. Brain Res Bull 145:53–58
79. Madhav N, Oppenheim B, Gallivan M, Mulembakani P, Rubin E, Wolfe N (2017) Pandemics: Risks, Impacts, and Mitigation. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Markoff L, Hayes EB, Chen RT, Ball R, Braun MM, Cetron M (2007) Neurological disease associated with 17D–204 yellow fever virus. AJR Am J Roentgenol 175:555–556
80. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77:683
81. Mann JM, Shandler L, Cushing AH (1982) Pediatric plague. N Engl J Med 302:238–246
82. Markoff L, Hayes EB, Chen RT, Ball R, Braun MM, Cetron M (2007) Neurologic disease associated with 17D–204 yellow fever virus. AJR Am J Roentgenol 175:555–556
83. McGavern DB, Kang SS (2011) Illuminating viral infections in the nervous system. Nat Rev Immunol 11:318–329
84. McGavern DB, Kang SS (2011) Illuminating viral infections in the nervous system. Nat Rev Immunol 11:318–329
85. McGavern DB, Kang SS (2011) Illuminating viral infections in the nervous system. Nat Rev Immunol 11:318–329
86. Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Markoff L, Hayes EB, Chen RT, Ball R, Braun MM, Cetron M (2007) Neurologic disease associated with 17D–204 yellow fever virus. AJR Am J Roentgenol 175:555–556
87. Meyer H, Ehmann R, Smith GL (2020) Smallpox in the post-eradication era. Viruses 12:138
88. Molloy S, O’Laoide R, Brett F, Farrell M (2000) The “Pulvinar” sign in variant Creutzfeldt-Jakob disease. AJR Am J Roentgenol 175:555–556
89. Monath TP, Vasconcelos PF (2015) Yellow fever. J Clin Virol 64:160–173
90. Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, Fonseca EBd, Ribeiro EM, Ventura LO, Neto NN, Arena JF, Rasmussen SA (2017) Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatrics 171:288–295
91. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, Chong WK, Hubank M, Pagnol V, Desforges M, Jacques TS, Talbot PJ, Breuer J (2016) Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 375:497–498
92. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Oghara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shi-mada S (2020) A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94:55–58
93. Musso D, Gubler DJ (2016) Zika virus. Clin Microbiol Rev 29:487–524
94. Musso D, Ko Al, Baud D (2019) Zika virus infection—after the pandemic. N Engl J Med 381:1444–1457
95. Nath A (2015) Neurologic complications of human immuno-deficiency virus infection. Continuum (Minneap Minn) 21:1557–1576
96. Nathanson N, Kew OM (2010) From emergence to eradication: the epidemiology of poliomyelitis reconstructed. Am J Epidemiol 172:1213–1229
97. Needham EJ, Chou SHY, Coles AJ, Menon DK (2020) Neu-rological implications of COVID-19 infections. Neurocrit Care 32:667–671
98. European Academy of Neurology (EAN) (2020) EANcore COVID-19. Retrieved from https://www.ean.org/eanco re-covid-19. Accessed 2 Oct 2020
99. Ofihia CE, Naseer A (2016) Spectrum of imaging appearances of intracranial cryptococcal infection in HIV/AIDS patients in the anti-retroviral therapy era. Clin Radiol 71:9–17
100. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T (2010) Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 9:1097–1105
101. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoibah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Sklit M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fiti JT (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382:e60
102. Parsons T, Banks S, Bae C, Gelber J, Alamhadi H, Tichauer M (2020) COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol 1–4
103. Patel PB, Spudich SS (2018) Global health neurology: HIV/ AIDS. Semin Neurol 38:238–246
104. Paules CI, Marston HD, Fauci AS (2019) Measles in 2019—going backward. N Engl J Med 380:2185–2187
105. Petersen LR, Jamieson DJ, Powers AM, Honein MA (2016) Zika virus. N Engl J Med 374:1552–1563
106. Pohl D, Alper G, Van Haren K, Kornberg E, Lucchetti CF, Tenembaum S, Belman AL (2016) Acute disseminated encephalomyelitis. Updat Inflamm CNS Syndr 87:S38–S45
107. Postels DG, Birbeck GL (2013) Cerebral malaria. Handb Clin Neurol 114:91–102
108. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B (2020) COVID-19–associated Acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 201187
109. Prentice MB, Rahalison L (2007) Plague. Lancet 369:1196–1207
110. Ragin AB, Wu Y, Gao Y, Keating S, Du H, Sammet C, Kettering CS, Epstein LG (2015) Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol 2:12–21
111. Rasheed A, Saeed S, Khan SA (2009) Clinical and laboratory findings in acute malaria caused by various plasmodium species. J Pak Med Assoc 59:220–223
112. Rosewell A, Clark G, Mabong P, Ropa B, Posanai E, Man NW, Dutta SR, Wickramasinghe W, Qi L, Ng JC, Mola G, Zwi AB, MacIntyre CR (2013) Concurrent outbreaks of cholera and peripheral neuropathy associated with high mortality among persons internally displaced by a volcanic eruption. PLoS ONE 8:e72566
113. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Selim MA, Al Mutairi M, Al Nakhi D, Al Aidaroos AY (2014) Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29:301–306
114. Sacks OW (1991) Awakenings. Pan Macmillan
115. Sagui E, Janvier F, Baize S, Foissaud V, Koulibaly F, Savini H, Sacks Y, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Maegye N, Aletti M, Granier H, Carmo T (2015) Severe Ebola virus infection with encephalopathy: evidence for direct virus neuroinvasion. Muscle Nerve 58:760–769
116. Salinas S, Schiavo G, Kremer EJ (2010) A hitchiker’s guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 8:645–655
respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis 41:1089–1096
158. Yang R (2018) Plague: recognition, treatment, and prevention. J Clin Microbiol 56:e01519-e11517
159. Ye M, Ren Y, Lv T (2020) Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 88:945–946. https://doi.org/10.1016/j.bbi.2020.04.017
160. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H (2004) Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics 113:e73-76
161. Zacharia TT, Law M, Naidich TP, Leeds NE (2008) Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 18:411–417
162. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, Fontanella MM (2020) SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 162(7):1491–1494. https://doi.org/10.1007/s00701-020-04374-x
163. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S (2020) Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 21:74
164. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38. https://doi.org/10.1056/NEJMoa2007575
165. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77(8):1018–1027. https://doi.org/10.1001/jamaneurol.2020.2065